This week, the S&P/TSX Composite Index continued its upward momentum. Investor sentiment remained cautiously optimistic amid easing inflation data and geopolitical developments, with the index hovering near record highs. With this in mind, several TSX-listed companies made significant headlines, offering fresh opportunities and insights for investors.
What the “Buzz”
Our Bullboards have up to 2 million pageviews a day. Get the inside scoop on conversations around the most significant trends and stock appreciations in our weekly wrap up.
Get “Buzz on the Bullboards” delivered to your inbox every third Thursday!
Buzz on the Bullboards | Sign Up Here
Tilray Brands (TSX:TLRY, Forum), a prominent name in the global cannabis industry, saw its medical division, Tilray Medical, achieve a major regulatory milestone in Europe. The company became the first to receive authorization from Italy’s Ministero della Salute to distribute medical cannabis flower for therapeutic use.
Operating through its wholly-owned subsidiary, FL Group, Tilray Medical will introduce three new cannabis flower varieties in Italy starting this June:
- Tilray THC 25 per cent
- Tilray THC 18 per cent
- Tilray THC 9 per cent / CBD 9 per cent
This development strengthens Tilray’s foothold in the European medical cannabis market, complementing its existing operations in Germany, Portugal, Poland, and the UK. For investors, this move signals Tilray’s positioning in a rapidly growing sector, with Italy potentially serving as a gateway to broader EU market penetration.
Bombardier (TSX:BBD, Forum) made waves through its defense division, Bombardier Defense, which announced a firm order from Swedish aerospace and defense company Saab for two Global 6500 aircraft. These jets will support Saab’s advanced surveillance and reconnaissance systems.
The Global 6500 boasts:
- A top speed of 956 km/h
- A maximum range of 12,223 km
- Steep approach certification and advanced wing design for versatile mission deployment
This order builds on the companies’ long-standing collaboration, including the GlobalEye airborne early warning and control system.
(Source: Bombardier.)
Bombardier Defense wants to carve out a niche in special mission aircraft, addressing critical needs in humanitarian aid, maritime patrol, and defense. The deal reinforces Bombardier’s dual strength in commercial aviation and defense innovation, making it a stock to watch for long-term growth.
Almonty Industries (TSX:AII, Forum), a global company involved in tungsten concentrate production, received a formal letter of recognition from the US House Select Committee on Strategic Competition with China. The letter highlights Almonty’s pivotal role in securing critical mineral supply chains amid rising geopolitical tensions.
Key points include:
- The importance of Almonty’s Sangdong Mine in South Korea, poised to become the largest tungsten producer outside China
- Plans to redomicile to the United States, positioning Almonty as the only US-based commercial-scale tungsten producer
- Potential collaboration with US defense contractors and inclusion in the National Defense Stockpile
This recognition could not only validate Almonty’s value but it would also open doors to US government partnerships and defense sector integration—an encouraging signal for investors seeking exposure to critical minerals and geopolitical tailwinds.
As the TSX continues to show resilience, these three companies—Tilray Brands, Bombardier, and Almonty Industries—demonstrate how innovation, partnerships, and regulatory breakthroughs can drive investor value. Whether it’s cannabis, aerospace, or critical minerals, the Canadian market is brimming with opportunity.
Investors should stay engaged with market developments and regularly reassess their portfolios to capitalize on emerging trends and maximize returns in a dynamic global environment.
For previous editions of Buzz on the Bullboards, click here.
Join the discussion: Find out what everybody’s saying about these stock on Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein.